Glenmark spinoff name Gilead VP Alessandro Riva as new CEO

pharmafile | March 7, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Gilead’s Dr Alessandro Riva, is stepping down from his position as the company’s Executive Vice President, Oncology Therapeutics to head an as yet unnamed Glenmark Pharmaceuticals spinoff company. Dr Riva will join the new firm as the company’s CEO.  

Having joined Gilead in 2017, Dr Riva played a critical role in driving the expansion of the Californian firm’s oncology programs. Riva also played a fundamental part in Gilead’s takeover of cancer immunotherapy firm Kite Pharma.

After leaving Gilead at the end of the month, Riva will head Glenmark’s 400 person spinoff firm. The Indian company’s spinoff will be mainly focused on cancer. The move comes just a week after Daniel O’Day took up his position as Gilead’s new CEO.

“Under Alessandro’s oversight, Gilead has expanded its work in the field of oncology and established itself as the leader in cell therapy with the acquisition of Kite,” said Dr John McHutchison, Chief Scientific Officer and Head of Research and Development.

In emphasising Gilead’s commitment to cancer, Dr McHutchison added: “We are well-positioned to continue to grow, and I am confident in the ability of Gilead and Kite to advance our pipeline of novel therapeutics for people living with cancer.”

Commenting on his own appointment, Riva said: “I’m looking forward to bringing my experience to lead the company and work together with highly experienced teams to deliver first-in-class therapies to the patients who need them the most.”

Glenmark’s New Jersey-headquartered spinoff will have locations across the globe including two R&D sites in Switzerland and an R&D centre in Mumbai.

Related Content

No items found

Latest content